Objectives: Invasive aspergillosis (IA) is a life-threatening infection in severely immunocompromised patients, especially those receiving intensive chemotherapy or undergoing haematopoietic stem cell transplantation. As the clinical diagnosis of IA is mostly based on biomarkers (galactomannan, b-D-glucan, PCR assays) indicating Aspergillus as the underlying pathogen, the effect of antifungal treatment on the performance of these parameters is still controversial. We evaluated the effect of antifungal treatment on the performance of an Aspergillus-specific PCR assay in bronchoalveolar lavage (BAL) samples.
Introduction
Invasive fungal infections (IFIs) are frequent and life-threatening infectious diseases in patients with severe immunosuppression, such as intensive, myeloablative chemotherapy or allogeneic stem cell transplantation. A significant proportion of IFIs consists of invasive mould infections, with invasive pulmonary aspergillosis (IPA) accounting for the majority of IFIs. Establishing the diagnosis of an IFI is based on criteria published by the European Organization for the Research and Treatment of Cancer/Mycoses Study Group (EORTC/MSG), initially published in 2002 and revised in 2008. 1 The risk for IFI increases with the extent of the underlying or therapeutic immunosuppression, and has a major impact on mortality and morbidity, despite a growing number of effective antifungal drugs, 2 as well as economic effects, with a mean additional treatment cost of more than US$50 000 per patient. 3 Diagnosing IFI, however, still remains a challenge. In a large autopsy-based retrospective analysis, only 25% of patients with IFI confirmed by autopsy were identified pre-mortem by culture-based or serological methods, underlining the difficulty in diagnosing IFI 4 by the available methods and emphasizing the need for novel serological and molecular markers. According to the EORTC/MSG criteria, only positive results from conventional cultures [excluding bronchoalveolar lavage (BAL)] and/or histological examination provide definitive proof of invasive aspergillosis (IA). However, as haematological patients at risk for IPA are usually in clinical conditions that rarely permit invasive diagnostic procedures (e.g. tissue sampling), the search for improved diagnostic tools for invasive infections caused by Aspergillus species has focused on novel molecular methods.
The detection of fungal nucleic acids using PCR assays has been shown to be a promising diagnostic approach. In addition to being potentially more sensitive than current culture-based methods, PCR can be designed to encompass a specific range of genera and specimen types. As sensitivity rates to specific antifungal drugs and therefore the clinical response are also dependent on the type of fungus identified, defining the genera and species of the fungus responsible has an enormous clinical impact. To date, PCR was not included in the 2008 revision of the EORTC/MSG IFI consensus criteria, 1 due to the broad plethora of methods and lack of standardization. However, much effort is ongoing in establishing standardization for PCR-based IPA diagnosis, 5 which may help integrate PCR into the next revision of the EORTC/MSG criteria. In order to detect (early) IPA by PCR, it may be more promising to investigate BAL samples, as Aspergillus infections are primarily air-borne pulmonary infections that only secondarily spread to the blood. In a previous study, we found a superior performance of BAL PCR as compared with blood PCR. 6 However, little is known about the influence of new antifungals on the performance of Aspergillus PCR assays. The majority of the available data were collected under treatment with older antifungal drugs, such as amphotericin B or itraconazole, if treatment data were reported at all. This is especially important as mould-active antifungal prophylaxis has been proven to reduce IPA incidence 7 and is increasingly established in haematological wards. Few groups have reported on the influence of antifungal treatment on PCR performance and have obtained contradictory results, 8, 9 but systematic data are lacking. Results from the AmBiLoad trial suggested a pronounced impairment of blood PCR performance under antifungal treatment. 10 Moreover, a stronger decrease of PCR sensitivity was observed for blood as compared with BAL. Controversially, another group saw an increase in the diagnostic performance of Aspergillus PCR assays under antifungal therapy, 9 although the authors hypothesized that a therapeutic bias might have contributed to that observation.
Two experimental animal models have shown that antifungal treatment had a pronounced influence on surrogate parameter [galactomannan (GM), PCR] performance; 11, 12 however, data concerning the influence of novel antifungal therapy and prophylaxis on the performance of surrogate markers in clinical routine are lacking.
Therefore, the influence of antifungal treatment on the performance of a nested Aspergillus PCR in BAL samples was systematically investigated.
Patients and methods

Study design
BAL samples submitted to our laboratory between January 2000 and February 2011, initially processed to detect Aspergillus DNA by a nested PCR assay, were retrospectively analysed to elucidate the influence of antifungal therapy on PCR performance.
Included in this analysis were haematological patients at high risk for fungal infections with new lung infiltrates detected by high-resolution CT scans, who had a minimum of one BAL sample tested by our nested PCR assay. Informed consent had been acquired prior to BAL sampling and analysis was done according to Good Clinical Practice guidelines as well as in concordance with the Declaration of Helsinki.
The trial was registered by ClinicalTrials.gov (identifier: NCT01448226).
Patient characteristics
Two-hundred-and-twenty-six BAL samples from 226 haematological patients at high risk for IA and pulmonary infiltrates were obtained between January 2000 and February 2011, and analysed by an Aspergillus-specific nested PCR assay as described previously. 13 For the patients' characteristics see Tables 1 and 2 .
The patients were treated in the following hospitals: University Hospitals of Mannheim, Wuerzburg, Cologne, Herne, Erlangen, Ulm, Halle/ Saale, Freiburg, Heidelberg and Dü sseldorf; Bone Marrow Transplantation Center Wiesbaden; and General Hospitals of Ludwigshafen, Passau, Frankfurt/Oder, Bielefeld and Trier (all in Germany).
To evaluate the influence of antifungal agents given prior to BAL sampling, a case was defined as having received antifungal therapy if the Reinwald et al.
drug exposure was more than one full daily dosage of the corresponding drug. Conventional and liposomal formulations of amphotericin B were considered one group ('amphotericin B-based formulations'). Oral and intravenous voriconazole were considered one course, and data on serum azole levels were not collected. Outcome data were only available for a minority of patients and were therefore not analysed. Data on prophylaxis versus empirical or definitive antifungal treatment approaches were not collected.
Definitions for classification
Patients were classified according to the revised EORTC/MSG criteria. 1 According to these criteria, 7 patients were classified as proven, 41 patients as having probable disease and 122 patients as having possible invasive fungal disease; the remaining 56 patients did not fulfil the EORTC/MSG criteria for invasive fungal disease.
For determination of PCR performance, all proven/probable patients (n ¼48) were evaluated while the remaining (n¼178) were used as the control population.
Radiological diagnostics
All patients received high-resolution CT scans of the lung prior to BAL sampling performed according to standardized techniques. 14 The CT scan results were analysed by a panel of local experienced radiologists.
BAL sampling
Bronchoscopy was performed according to the guidelines of the German Society of Pneumology, 15 usually 1 -3 days after suggestive radiological findings and clinical conditions suspicious of IA were met. Up to eight aliquots of 20 mL of sterile saline solution were instilled; the first aspirate was discarded and the following aspirates were used for diagnostic work-up. The site of BAL sampling was always directed by the CT-based localization of lung infiltrates. The samples were shipped immediately after BAL sampling; the usual delivery time was 24 h and the specimens were sent at ambient temperature. The diagnostic work-up was performed according to the guidelines of the Infectious Diseases Working Party of the German Society of Hematology and Oncology first published in 1999 16 and later the revised versions. 14, 17 An aliquot of 5 mL was sent to the scientific laboratory of our department where PCR testing was performed subsequently.
DNA preparation and PCR analysis
Total DNA was extracted from 1.5 mL of the leucocyte pellet of BAL samples and processed by an experienced technical assistant uninformed of the clinical data, according to the DNA extraction and nested PCR protocol published by Skladny et al. 13 
Statistical analysis
Sensitivity rates, specificity rates, positive predictive values, negative predictive values, diagnostic ORs as well as statistical analysis by MannWhitney U-test were determined/performed using GraphPad Prism for 
Results
The impact of antifungal treatment on PCR performance in BAL was based on data from 226 patients.
Mould-active antifungal treatment prior to BAL sampling
Of 226 patients, 146 (64.6%) patients received one or more doses of mould-active antifungals prior to BAL sampling, either therapeutically or prophylactically. In patients defined as having proven/probable IA, 35/48 (72.9%) patients had received antifungals prior to BAL sampling, whereas in the control group only 111/178 (62.4%) patients had been pre-treated. The antifungal regimens are listed in Table 3 . Forty-four patients received more than one mould-active antifungal prior to BAL sampling, either as combination therapy (n¼ 5) or sequentially (n¼ 39) as empirical treatment.
PCR performance in all evaluable patients regardless of prior treatment Positivity of PCR was significantly more frequent in the proven/ probable group compared with the controls (Mann -Whitney U-test; P,0.0001). Twenty-two patients with possible IA and PCR performance in proven/probable patients with two or more antifungals prior to BAL sampling (n 512)
In probable/proven IA patients according to EORTC/MSG criteria with two or more antifungals prior to BAL sampling, 2/12 patients were found positive for Aspergillus DNA in BAL fluid, yielding sensitivity and specificity values of 0.17 (95% CI, 0.05 -0.45) and 0.87 (95% CI, 0.82 -0.92), respectively, with a PLR of 1.3, an NLR of 1.0 and a diagnostic OR of 1.4. Diagnostic parameters for BAL PCR in relation to antifungal treatment/prophylaxis are displayed in Table 3 .
A significant influence of antifungal treatment was observed if more than one antifungal regimen was applied prior to BAL sampling (Mann -Whitney U-test: no versus one antifungal, P .0.78; one versus at least two antifungals, P,0.002; and no versus at least two antifungals, P,0.04). This is shown in Figure 1 .
PCR performance with regard to different antifungals used as monotherapy
Data from the analysis of IPA patients receiving mould-active antifungal monotherapy (n ¼23 proven/probable patients) prior to BAL sampling are presented in Table 5 . There was no significant difference in BAL PCR performance between patients receiving amphotericin B-based treatment (n¼ 6), echinocandin treatment (n¼ 3) or mould-active triazole treatment/prophylaxis (n¼ 14). PCR performance in relation to antifungal agents is described in Table 4 and detailed in Figure 2 .
PCR performance when comparing proven/probable patients versus patients without IA
Due to the significant number of positive PCR results in the cases defined as possible based on EORTC criteria (n¼ 122), we performed a subanalysis by comparing the results from patients defined as probable/proven (n¼ 48) against patients without IA (n¼ 56) and leaving out the possible cases (n¼122). This led to a significant increase in the specificity, PLR and diagnostic OR (Table S1 , available as Supplementary data at JAC Online).
Discussion
We systematically investigated the influence of mould-active antifungal treatment on the diagnostic performance of an Aspergillus-specific nested PCR assay in BAL samples of Reinwald et al.
haematological patients at high risk for IA. The respective sensitivity and specificity rates of BAL PCR in all patients, regardless of antifungal treatment or prophylaxis, were 0.58 and 0.87 for proven/probable patients. Compared with previously published studies, this lower overall sensitivity is explained by the strict case definition of probable patients introduced by the EORTC criteria and the antifungal therapy with novel antifungals. For patients with proven IA we observed higher sensitivity rates as compared with probable patients (0.71 versus 0.56).
In a literature review of BAL PCR performance published by Tuon, 18 a pronounced observation can be made: the median sensitivity of BAL PCR in studies not using the EORTC/MSG 2002 criteria (1993 -2002 , n ¼11) is 100%, whereas a distinct decrease in sensitivity can be observed for the later studies using the EORTC 2002 criteria (2002 -04, n¼ 4) . This might be explained by several factors, as described below.
The definition of suspected IA varies greatly among the studies in the earlier trials, as the first definition of IA by the EORTC was published in 2002 19 and later redefined in 2008, 1 which might explain the discrepancies among the studies reported. Prior to the definition by the EORTC, probable/proven IA was usually defined by either autopsy or positive culture. The sensitivity of PCR in proven patients is known to be better than in those defined as probable, 18 which might explain the sensitivity values observed in the early publications. In some published studies, probable cases were even defined solely by host factors and chest CT-scan results, without having microbiological criteria (e.g. Verweij et al. 20 and Buchheidt et al. 21 ). In contrast, with the EORTC/MSG criteria, additional surrogate parameters such as GM as well as a strict definition of immunosuppression (host factors) were included, which probably impacted on the diagnostic performance in all trials following 2002. After the definition of probable cases was changed and more probable, culture-negative cases were included in the trials in order to achieve a relevant number of cases, the overall sensitivity rates decreased. Indeed, recent publications concerning Aspergillus-specific PCR in BAL samples suggest similar sensitivities, 22, 23 which might reflect that more probable and less proven patients are included; however, this represents current routine clinical reality.
Another significant factor that impacts on the performance of surrogate parameters is the availability and efficacy of novel antifungals that have been introduced into clinical practice, and the prophylactic use of mould-active antifungals in order to decrease the incidence of IA. 7,24 -26 In high-risk haematological patients, routine clinical management in some centres encompasses the application of a mould-active antifungal after 72 -96 h of fever despite broad-spectrum antibiotics, as this has been shown to confer a higher response rate. 27 This and the increased use of broad-spectrum azole prophylaxis often leads to the situation that BAL sampling is performed under antifungal treatment or when the patient is clinically deteriorating rapidly. In general, antibiotic treatment has been repeatedly shown to decrease the sensitivity of culture-based tests, even for antifungals and mycological diagnostics. 28 The profound influence of antifungal medication on the performance of other surrogate parameters is hinted at by Marr et al., 29 who described a significant impairment of GM in patients under antifungal therapy, an observation that was confirmed in a recent meta-analysis. 30 The effect of antifungal therapy on other surrogate parameters suggests reduced sensitivity rates with antifungal therapy for GM, 29 whereas no influence of antifungal therapy on b-D-glucan performance in a (single-centre retrospective) study was described. 31 In relation to BAL PCR performance, previous trials from the 1990s, such as those published by Verweij et al. 20 and Bretagne et al., 32 did not provide information on empirical antifungal therapy prior to BAL sampling. However, in more recent trials, Influence of novel antifungals on Aspergillus PCR detection in BAL such as the ones by Musher et al. 9 and Frealle et al., 23 limited information concerning antifungal medication is given.
Our systematic analysis shows that a significant decrease of BAL PCR performance is observed for patients having received more than one mould-active antifungal prior to BAL sampling. This is in line with observations by Lass-Flö rl et al., 8 who analysed clinical samples by Aspergillus PCR during antifungal therapy and reported reduced sensitivities; an observation we shared for patients analysed for blood PCR within the AmBiLoad trial. 10 Furthermore, data from pre-clinical studies show a significant impairment of surrogate parameter performance, depending not only on the number of antifungals but also suggesting differential effects for different antifungals. 11, 12 As the armamentarium of effective, mould-active antifungals increases and performing combination antifungal therapy becomes more popular, the amount of antifungal medication applied prior to BAL sampling increases even further. Of all the patients receiving antifungals in a recent monocentric study, 9% were administered a simultaneous combination therapy. 33 Additionally, as using broad-spectrum triazole prophylaxis in high-risk patients is established in routine clinical management, having a BAL sample without prior antifungal medication becomes the exception rather than the rule.
Our data suggest that BAL is best performed with minimal antifungal treatment prior to BAL sampling, because PCR sensitivity decreases significantly if more than one antifungal regimen is applied prior to BAL sampling. On the other hand, we did not observe a difference in PCR sensitivity values between patients with or without treatment with one antifungal. This might underline the feasibility of performing BAL even for patients on broad-spectrum azole prophylaxis and does not negate the usefulness of a BAL in obtaining a valid diagnosis. On the other hand, the PCR testing of BAL samples after treatment with more than one antifungal is doubtful.
There are two limitations to our study. First, the number of patients in each of the three treatment categories is rather small, despite the high number of total cases analysed. However, this is a limitation that can hardly be circumvented when investigating diagnostic tools in IA. In order to achieve an ample number of proven/probable IA patients, a huge amount of cases with a high pre-test probability of IA need to be analysed, as is demonstrated by our multicentre, retrospective approach. Additionally, as autopsy rates decline worldwide, 34 obtaining proven cases as the gold standard of diagnostics becomes increasingly difficult. Furthermore, the number of proven/probable cases in our study (n¼ 48) is in line with or exceeds the two other major studies investigating treatment effects on surrogate parameter performance (n ¼46 blood samples; n ¼21 BAL samples) for diagnosing IA. 29, 35 Second, we evaluated the absolute number of antifungal agents prior to BAL sampling and not the duration of previous antifungal treatment. Sanguinetti et al. 36 showed that the sensitivity of BAL GM dropped from .80% to 0% after .72 h of antifungal treatment was applied. However, in usual clinical practice, a change in the antifungal regimen in combination with BAL sampling is performed because of lack of efficacy in a clinically deteriorating patient, regardless of the time of prior antifungal treatment. Therefore, we did not collect data on the duration of prior antifungal treatment in our trial; however, further studies should address that issue in more detail.
In conclusion, performing Aspergillus-specific PCR testing in BAL samples from immunocompromised patients is a feasible approach, but its performance is decreasing with more than one mould-active antifungal regimen prior to BAL sampling. As we found no significant difference in BAL PCR performance between patients receiving one or no antifungal, the usefulness of testing surrogate parameters in BAL is probably not impaired in patients who are on broad-spectrum azole prophylaxis. Therefore, performing BAL and testing surrogate parameters (BAL GM, BAL PCR) is recommended as early as possible in patients with suspected IA who are clinically deteriorating under IA prophylaxis, in order to confirm the diagnosis or identify other causes.
